• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Participating Faculty: Characterizing Pulmonary Hypertension-Related Hospitalization Costs Among Medicare Advantage or Commercially Insured Patients With Pulmonary Arterial Hypertension: A Retrospecti

Publication
Article
Supplements and Featured PublicationsCharacterizing Pulmonary Hypertension–Related Hospitalization Costs Among Medicare Advantage or Co
Volume 21
Issue 3 Suppl

Actelion Pharmaceuticals Ltd

This supplement to The American Journal of Managed Care provides an overview of a retrospective claims database study with results showing that pulmonary arterial hypertension is characterized by long durations and high incurred costs of pulmonary hypertension— related hospitalizations and readmissions over 1 year.This study and supplement were sponsored by .

Faculty

James P. Burke, PhD

Senior Researcher

Health Economics and Outcomes

Research

Optum

Eden Prairie, Minnesota

Paul Buzinec, MS

Associate Director

Health Economics and Outcomes

Research

Optum

Eden Prairie, Minnesota

William Drake III, PharmD

Associate Director

Medical Managed Markets and

Health Economics and

Outcomes Research

Actelion Pharmaceuticals US, Inc

South San Francisco, California

Elke Hunsche, PhD

Senior Director

Global Market Access and Pricing

Actelion Pharmaceuticals Ltd

Allschwil, Switzerland

Mitchell Nagao, PharmD, MBA

Senior Director

Medical Affairs and Health

Economics and Outcomes

Research

Actelion Pharmaceuticals US, Inc

South San Francisco, California

Etienne Régulier, PhD

Associate Director

Global Market Access and Pricing

Actelion Pharmaceuticals Ltd

Allschwil, Switzerland

Faculty Disclosures

These faculty report relationships with the following organizations:

James P. Burke, PhD

Employment: Optum, which received funding from Actelion Pharmaceuticals Ltd for the research described in the present manuscript

Paul Buzinec, MS

Employment: Optum, which received funding from Actelion Pharmaceuticals Ltd for the research described in the present manuscript

William Drake III, PharmD

Employment and stock ownership: Actelion Pharmaceuticals US, Inc

Elke Hunsche, PhD

Employment and stock ownership: Actelion Pharmaceuticals Ltd

Mitchell Nagao, PharmD, MBA

Employment and stock ownership: Actelion Pharmaceuticals US, Inc

Etienne Régulier, PhD

Employment and stock ownership: Actelion Pharmaceuticals Ltd

Signed disclosures are on file at the office of The American Journal of Managed Care, Plainsboro, New Jersey.

© 2024 MJH Life Sciences
AJMC®
All rights reserved.